SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________________________ to _________________________ Commission File Number: 001-36790 Predictive Oncology Inc. (Exact name of registrant as specified in its charter) | Delaware | 33-1007393 | | --- | --- | | (State or other jurisdiction of | (I.R.S. Employer | | incorporation or organization) | Identification No.) | | 91 43r ...

Predictive Oncology, Inc. (NASDAQ:POAI) Q2 2023 Earnings Conference Call August 10, 2023 5:30 PM ET Company Participants Glenn Garmont - Managing Director at LifeSci Partners Raymond Vennare - Chief Executive Officer and Chairman of the Board Bob Myers - Chief Financial Officer Pamela Bush - Chief Business Officer Conference Call Participants Operator Good day, and thank you for standing by. Welcome to the Predictive Oncology Q2 2023 Earnings Conference Call. At this time, all participants are in a listen-o ...

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________________________ to _________________________ Commission File Number: 001-36790 Predictive Oncology Inc. (Exact name of registrant as specified in its charter) | Delaware | 33 ...

Financial Data and Key Metrics Changes - As of March 31, 2023, cash and cash equivalents decreased to $18.6 million from $22.1 million as of December 31, 2022 [29] - Shareholders' equity stood at $18.6 million compared to $21.8 million as of December 31, 2022 [77] - First quarter 2023 revenue was $0.2 million, down from $0.3 million in the first quarter of 2022, with a gross margin of 50% compared to 65% in the previous year [77] Business Line Data and Key Metrics Changes - The PeDAL platform is highlighted as a significant asset, with the ability to predict tumor responses with 92% accuracy, aiding in drug discovery [8] - The company has launched 11 cancer therapies currently on the market and is sponsoring an additional 160 compounds [9] Market Data and Key Metrics Changes - The company is positioned to participate in the $1 billion artificial intelligence drug discovery market, projected to grow annually at a compound rate of more than 30% [51] Company Strategy and Development Direction - The company aims to leverage its PeDAL platform and partnerships to mitigate clinical risks and enhance drug discovery processes [82] - Recent partnerships with Cancer Research Horizon (CRH) and Cvergenx are expected to expand the company's reach in oncologic drug development [85][87] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about revenue potential in the next six months, indicating that it will be greater than the previous year [46] - The company is working towards breakeven, with expectations of achieving this within the next 12 months [103] Other Important Information - The company has no debt, indicating a strong balance sheet [29] - A recent lawsuit was mentioned, with management asserting a strong commitment to resolving it with minimal impact on investors [14] Q&A Session Summary Question: What is the timeline for breakeven and how many molecules have been looked at under the partnership with Cancer Research? - Management confirmed that they are working on one compound, and successful development will trigger financial milestones [35] Question: Can you clarify the situation regarding David Smith stepping down from the Board? - Management explained that David Smith stepped down due to a conflict with his law firm but will remain as a Board adviser and lead corporate counsel [99] Question: What are the expectations for revenue growth in the next quarter? - Management expressed hope for revenue growth within the fiscal year, noting that no machines were sold in the last quarter but a new agreement in Canada was signed [103]

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________________________ to _________________________ Commission File Number: 001-36790 Predictive Oncology Inc. (Exact name of registrant as specified in its charter) Del ...

Financial Data and Key Metrics Changes - The company is transitioning from R&D and product development to the validation, commercialization, and launch of its PEDAL drug discovery platform [15][28] - The sales cycle for the PEDAL platform is approximately 12 months, which impacts revenue recognition [46][48] Business Line Data and Key Metrics Changes - The company has partnered with Cancer Research Horizons to integrate its PEDAL platform into drug discovery processes, enhancing visibility and credibility in the market [15][16] - A collaboration with Cvergenx, Inc. aims to develop a genomics-based approach to precision radiation therapy using the PEDAL platform [18][20] Market Data and Key Metrics Changes - The company is focusing on oncology drug discovery and development, leveraging its unique AI capabilities and biorepository of tumor samples [8][9] - The market for AI in biopharma is growing, with increasing adoption of AI technologies for drug discovery [50] Company Strategy and Development Direction - The company is rebranding and repositioning itself to emphasize its unique AI-driven approach to drug discovery [5][8] - There is a strategic focus on expanding the intellectual property portfolio and enhancing partnerships with academic and research institutions through the Accelerating Compound Exploration program [10][21] Management's Comments on Operating Environment and Future Outlook - Management acknowledges the challenges of being an innovator in the biopharma space, emphasizing the need to demonstrate how their platform fits into existing workflows [45][48] - The FDA's acceptance of AI technologies is seen as a positive development for the company's future prospects [72] Other Important Information - The company has engaged a leading investor relations firm to raise awareness among Wall Street constituents [27] - A new Scientific Advisory Board is being formed to focus on emerging market opportunities in AI and oncology [25][26] Q&A Session Summary Question: Did the departure of Dr. Julia Kirshner hurt the company? - Management stated that her departure did not hinder technological progress, as the necessary expertise remains within the company [34][40] Question: What is the expected timeline for achieving breakeven status? - The CFO indicated that predicting a timeline for breakeven is challenging due to the variability in sales cycles and contract milestones [62] Question: What is the timeframe from signing a contract to receiving the first payment? - The company expects initial payments within 10 to 12 weeks after contract signing, depending on project size [68][70] Question: Will key executives purchase stock to show confidence in the company? - Management expressed interest in purchasing stock but is currently in a blackout period preventing such actions [89][91] Question: What is the target share price post-reverse split? - The management indicated that the ideal post-split share price would be in the range of $3.50 to $4.50, but this will depend on market conditions at the time [96][100] Question: How does the reverse split benefit shareholders? - Management clarified that while the reverse split does not change the actual value, a higher share price could attract more investors [110][111]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2022. ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER: 001-36790 PREDICTIVE ONCOLOGY INC. (Exact name of registrant as specified in its charter) Delaware 33-1007393 (State or other jurisdiction (IRS Employe ...

Predictive Oncology Inc. (NASDAQ:POAI) Q3 2022 Earnings Conference Call November 11, 2022 12:00 PM ET Company Participants Theresa Ferguson - Investor Relations Raymond Vennare - Chairman and Chief Executive Officer Pamela Bush - Senior Vice President of Strategic Sales and Business Development Bob Myers - Chief Financial Officer and Site Leader, Skyline Medical Conference Call Participants Michael Broadbent - Bedrock Group Inc. Operator Good day, ladies and gentlemen, and thank you for standing by. Welcome ...

[PART I. FINANCIAL INFORMATION](index=4&type=section&id=PART%20I.%20FINANCIAL%20INFORMATION) [Unaudited Condensed Consolidated Financial Statements](index=4&type=section&id=Item%201.%20Unaudited%20Condensed%20Consolidated%20Financial%20Statements) The company's financial statements show a net loss of $17.8 million and reduced assets due to a goodwill impairment [Condensed Consolidated Balance Sheets](index=4&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) Total assets decreased to $33.2 million, driven by a full goodwill impairment and a decline in cash reserves Key Balance Sheet Items | Balance Sheet Items | September 30, 2022 (unaudited) | December 31, 2021 (audited) | | :--- | :--- | :--- | | Cash and Cash Equivalents | $25,393,738 | $28,202,615 | | Total Current Assets | $26,857,321 | $29,458,273 | | Goodwill | $0 | $6,857,790 | | **Total Assets** | **$33,166,209** | **$43,771,271** | | Total Current Liabilities | $3,468,078 | $3,240,508 | | **Total Liabilities** | **$3,573,331** | **$3,505,587** | | **Total Stockholders' Equity** | **$29,592,878** | **$40,265,684** | - Goodwill was **fully impaired**, decreasing from **$6.9 million** at the end of 2021 to zero as of September 30, 2022[10](index=10&type=chunk) [Condensed Consolidated Statements of Net Loss](index=5&type=section&id=Condensed%20Consolidated%20Statements%20of%20Net%20Loss) The nine-month net loss widened to $17.8 million, primarily due to a $7.2 million goodwill impairment charge Key P&L Metrics | Metric | Q3 2022 | Q3 2021 | Nine Months 2022 | Nine Months 2021 | | :--- | :--- | :--- | :--- | :--- | | Revenue | $455,827 | $313,663 | $1,141,986 | $944,187 | | Gross Profit | $347,676 | $203,498 | $790,317 | $593,387 | | Loss on goodwill impairment | $0 | $2,813,792 | $7,231,093 | $2,813,792 | | **Net Loss** | **$(4,059,484)** | **$(5,438,017)** | **$(17,821,524)** | **$(11,900,662)** | | Loss per share (basic and diluted) | $(0.05) | $(0.08) | $(0.25) | $(0.23) | [Condensed Consolidated Statements of Stockholders' Equity](index=6&type=section&id=Condensed%20Consolidated%20Statements%20of%20Stockholders'%20Equity) Stockholders' equity decreased by $10.7 million to $29.6 million, driven by a net loss partially offset by capital raising - Total stockholders' equity declined by **$10.7 million** during the first nine months of 2022, from $40.3 million to $29.6 million[13](index=13&type=chunk) - The company's accumulated deficit increased by **$17.8 million**, from $(128.0) million to $(145.9) million, due to the net loss incurred during the period[13](index=13&type=chunk) - In May 2022, the company issued **12,000,000 shares and warrants** in a private offering, increasing additional paid-in capital by approximately **$6.4 million**[13](index=13&type=chunk) [Condensed Consolidated Statements of Cash Flows](index=8&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) Net cash decreased by $2.8 million, with operating cash burn partially offset by $6.7 million from financing activities Key Cash Flow Activities | Cash Flow Activity (Nine Months Ended Sep 30) | 2022 | 2021 | | :--- | :--- | :--- | | Net cash used in operating activities | $(9,135,812) | $(8,464,821) | | Net cash used in investing activities | $(412,096) | $(820,233) | | Net cash provided by financing activities | $6,739,031 | $50,378,237 | | **Net increase (decrease) in cash** | **$(2,808,877)** | **$41,093,183** | | **Cash at end of period** | **$25,393,738** | **$41,771,515** | [Notes to Condensed Consolidated Financial Statements](index=9&type=section&id=Notes%20to%20Condensed%20Consolidated%20Financial%20Statements) The notes detail accounting policies, business segments, goodwill impairment, and management's view on capital sufficiency - The company operates in four primary business areas: drug response prediction (Helomics), in vitro models for oncology (zPREDICTA), contract research for solubility (Soluble Biotech), and medical fluid waste disposal systems (Skyline)[19](index=19&type=chunk) - Management believes existing capital resources of **$25.4 million** will be sufficient to support the operating plan for the next twelve months and beyond[20](index=20&type=chunk) - A goodwill impairment charge of **$7,231,093** related to the zPREDICTA reporting unit was recorded, reducing its goodwill balance to zero as of June 30, 2022[85](index=85&type=chunk)[86](index=86&type=chunk) - On September 15, 2022, CEO J. Melville Engle announced his retirement, and the company recorded a liability of **$741,505** for severance and other benefits[112](index=112&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=24&type=section&id=Item%202.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses increased revenue, a wider net loss due to goodwill impairment, and its strategic focus on key segments - The company will focus its resources on the **Helomics** (AI-powered drug response prediction) and **zPREDICTA** (3D cell culture models) segments[119](index=119&type=chunk) - The company believes its existing capital of **$25.4 million** will be sufficient to support its operating plan for the next twelve months and beyond, but may seek additional capital[144](index=144&type=chunk) - In May 2022, the company raised capital through two offerings, selling an aggregate of **12 million shares** of common stock at $0.60 per share and issuing warrants[89](index=89&type=chunk)[90](index=90&type=chunk)[147](index=147&type=chunk) [Results of Operations](index=27&type=section&id=Results%20of%20Operations) Revenue increased due to the zPREDICTA acquisition, while expenses rose from G&A costs and a significant goodwill impairment Nine-Month Operational Performance Comparison | Expense/Income (Nine Months Ended Sep 30) | 2022 | 2021 | Change | | :--- | :--- | :--- | :--- | | Revenue | $1,141,986 | $944,187 | $197,799 | | General and administrative expense | $8,063,265 | $7,410,208 | $(653,057) | | Operations expense | $2,657,314 | $1,791,543 | $865,771 | | Sales and marketing expense | $908,867 | $447,298 | $461,569 | | Loss on goodwill impairment | $7,231,093 | $2,813,792 | $4,417,301 | - The increase in revenue for the nine-month period was primarily driven by **$261,099** from the zPREDICTA division[125](index=125&type=chunk) - The increase in G&A expenses for the nine-month period was mainly due to costs from the **CEO's retirement** and increased headcount from the zPREDICTA acquisition, offset by lower professional fees[130](index=130&type=chunk) [Liquidity and Capital Resources](index=29&type=section&id=Liquidity%20and%20Capital%20Resources) The company holds $25.4 million in cash, with an $8.9 million equity line restricted until May 2023 - The company had **$25.4 million in cash** as of September 30, 2022, after incurring a net loss of $17.8 million for the nine-month period[143](index=143&type=chunk) - Net cash provided by financing activities was **$6.7 million** for the nine months ended September 30, 2022, compared to **$50.4 million** in the prior-year period[142](index=142&type=chunk) - The company has an equity line with an available balance of **$8,877,820**, but agreed not to access it until May 18, 2023, as part of the May 2022 offerings[143](index=143&type=chunk)[155](index=155&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=32&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) As a smaller reporting company, this disclosure is not required - Disclosure is not required for this item[158](index=158&type=chunk) [Controls and Procedures](index=32&type=section&id=Item%204.%20Controls%20and%20Procedures) Disclosure controls were deemed ineffective due to a material weakness in accounting expertise for complex transactions - The CEO and CFO concluded that disclosure controls and procedures were **not effective** as of September 30, 2022[160](index=160&type=chunk) - A **material weakness** was identified: the company has not maintained adequate accounting resources with sufficient understanding of U.S. GAAP for complex technical accounting transactions[161](index=161&type=chunk) - To remediate the weakness, the company has **hired additional accounting resources** with the required experience[162](index=162&type=chunk) [PART II. OTHER INFORMATION](index=32&type=section&id=PART%20II.%20OTHER%20INFORMATION) [Legal Proceedings](index=33&type=section&id=Item%201.%20Legal%20Proceedings) The company reported no material legal proceedings - None[165](index=165&type=chunk) [Risk Factors](index=33&type=section&id=Item%201A.%20Risk%20Factors) Readers are referred to the company's 2021 Annual Report on Form 10-K for detailed risk factors - Readers are referred to the risk factors detailed in the Annual Report on Form 10-K for the year ended December 31, 2021[165](index=165&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=33&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) The company issued 29,346 unregistered shares for professional services under a Securities Act exemption - In the first nine months of 2022, the company issued **29,346 unregistered shares** of common stock in exchange for $25,000 worth of professional research services[166](index=166&type=chunk) - The sale was exempt from registration under **Section 4(a)(2)** of the Securities Act[167](index=167&type=chunk) [Defaults Upon Senior Securities](index=33&type=section&id=Item%203.%20Defaults%20Upon%20Senior%20Securities) The company reported no defaults upon senior securities - None[168](index=168&type=chunk) [Mine Safety Disclosures](index=33&type=section&id=Item%204.%20Mine%20Safety%20Disclosures) This item is not applicable to the company - Not applicable[169](index=169&type=chunk) [Other Information](index=33&type=section&id=Item%205.%20Other%20Information) This item is not applicable - Not applicable[170](index=170&type=chunk)

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________________________ to _________________________ Commission File Number: 001-36790 Predictive Oncology Inc. (Exact name of registrant as specified in its charter) Delaware 33-100 ...